

In the Claims

Claims 1-72 (Cancelled).

Claim 73 (New): An isolated polypeptide comprising:

- (a) SEQ ID NO: 68;
- (b) SEQ ID NO: 70 or 72, wherein said polypeptide has alpha-2-macroglobulin-like proteinase inhibitor activity;
- (c) a polypeptide that has at least 85% identity to SEQ ID NO: 68 over the full length of SEQ ID NO: 68, wherein said polypeptide has alpha-2-macroglobulin-like proteinase inhibitor activity; or
- (d) a polypeptide that has at least 95% identity to SEQ ID NO:70 or SEQ ID NO:72 over the full length of SEQ ID NO: 70 or 72, wherein said polypeptide has alpha-2-macroglobulin-like proteinase inhibitor activity.

Claim 74 (New): The isolated polypeptide of claim 73, wherein the polypeptide consists of SEQ ID NO: 68.

Claim 75 (New): The isolated polypeptide of claim 73, wherein said polypeptide comprises SEQ ID NO: 70 and has alpha-2-macroglobulin-like proteinase inhibitor activity.

Claim 76 (New): The isolated polypeptide of claim 73, wherein said polypeptide consists of SEQ ID NO:70 and has alpha-2-macroglobulin-like proteinase inhibitor activity.

Claim 77 (New): The isolated polypeptide of claim 73, wherein said polypeptide has at least 85% identity to SEQ ID NO: 68 over the full length of SEQ ID NO: 68 and has alpha-2-macroglobulin-like proteinase inhibitor activity.

Claim 78 (New): The isolated polypeptide of claim 77, wherein the sequence identity is greater than 90%.

Claim 79 (New): The isolated polypeptide of claim 77, wherein the sequence identity is greater than 95%.

Claim 80 (New): The isolated polypeptide of claim 77, wherein the sequence identity is greater than 98%.

Claim 81 (New): The isolated polypeptide of claim 77, wherein the sequence identity is greater than 99%.

Claim 82 (New): The isolated polypeptide of claim 73, wherein said polypeptide has at least 95% identity to SEQ ID NO:70 over the full length of SEQ ID NO: 70 and has alpha-2-macroglobulin-like proteinase inhibitor activity.

Claim 83 (New): The isolated polypeptide of claim 82, wherein the sequence identity is greater than 96%.

Claim 84 (New): The isolated polypeptide of claim 82, wherein the sequence identity is greater than 97%.

Claim 85 (New): The isolated polypeptide of claim 82, wherein the sequence identity is greater than 98%.

Claim 86 (New): The isolated polypeptide of claim 82, wherein the sequence identity is greater than 99%.

Claim 87 (New): The isolated polypeptide of claim 73, wherein said polypeptide comprises SEQ ID NO:72 and has alpha-2-macroglobulin-like proteinase inhibitor activity.

Claim 88 (New): The isolated polypeptide of claim 73, wherein said polypeptide consists of SEQ ID NO:72 and has alpha-2-macroglobulin-like proteinase inhibitor activity.

Claim 89 (New): The isolated polypeptide of claim 73, wherein said polypeptide has at least 95% identity to SEQ ID NO:72 over the full length of SEQ ID NO: 72 and has alpha-2-macroglobulin-like proteinase inhibitor activity.

Claim 90 (New): The isolated polypeptide of claim 89, wherein the sequence identity is greater than 96%.

Claim 91 (New): The isolated polypeptide of claim 89, wherein the sequence identity is greater than 97%.

Claim 92 (New): The isolated polypeptide of claim 89, wherein the sequence identity is greater than 98%.

Claim 93 (New): The isolated polypeptide of claim 89, wherein the sequence identity is greater than 99%.

Claim 94 (New): A pharmaceutical composition comprising the isolated polypeptide of claim 73 and a pharmaceutically acceptable carrier.